

## 財務ハイライト | Financial Summary

日本基準 (J-GAAP)

	'08/3	'09/3	'10/3	'11/3	'12/3	'13/3
売上高	¥1,896,539	¥1,788,223	¥1,620,915	¥1,982,435	¥1,947,884	¥1,952,492
営業利益	102,397	2,114	51,455	87,957	60,688	45,016
経常利益 (損失)	92,790	(32,624)	34,957	84,091	50,714	50,252
親会社株主に帰属する当期純利益 (損失)	63,083	(59,164)	14,723	24,434	5,587	(51,076)
総資産	2,358,929	2,022,553	2,383,906	2,367,314	2,336,953	2,472,091
自己資本	768,110	544,366	575,368	522,473	486,235	496,500
純資産	1,006,046	775,628	821,436	758,886	720,901	747,482
営業活動によるキャッシュ・フロー	156,578	78,428	132,872	176,228	124,491	171,595
投資活動によるキャッシュ・フロー	(182,679)	(206,237)	(269,402)	(155,987)	(123,975)	(165,772)
フリー・キャッシュ・フロー	(26,101)	(127,809)	(136,530)	20,241	516	5,823
財務活動によるキャッシュ・フロー	7,090	112,539	168,709	17,985	2,054	(36,009)
設備投資額 (十億円)	142.5	134.1	103.2	98.7	155.1	116.1
減価償却費 (十億円)	125.0	140.7	116.1	147.0	114.9	115.5
研究開発費 (十億円)	105.4	131.1	117.3	138.1	122.3	125.0
売上高営業利益率 (%)	5.4	0.1	3.2	4.4	3.1	2.3
売上高当期純利益率 (%)	3.3	(3.3)	0.9	1.2	0.3	(2.6)
売上高研究開発費比率 (%)	5.6	7.3	7.2	7.0	6.3	6.4
有利子負債 (十億円)	673.9	795.4	997.9	1,040.3	1,053.0	1,060.6
D/Eレシオ (倍)	0.7	1.0	1.2	1.4	1.5	1.4
自己資本比率 (%)	32.6	26.9	24.1	22.1	20.8	20.1
キャッシュ・フロー対有利子負債比率	4.3	10.1	7.5	5.9	8.5	6.2
インタレスト・カバレッジ・レシオ (倍)	13.2	6.5	11.0	13.7	10.2	13.2
金融収支 (十億円)	(2.8)	(2.7)	(5.0)	(6.3)	(4.7)	(5.4)
ROE (%)	8.1	(9.0)	2.6	4.5	1.1	(10.4)
ROA (%)	2.7	(2.7)	0.7	1.0	0.2	(2.1)
1株当たり当期純利益 (損失) (円)	38.20	(35.84)	8.92	14.86	3.42	(31.25)
1株当たり純資産 (円)	465.21	329.74	348.52	319.61	297.45	303.74
1株当たり配当金 (円)	12.00	9.00	6.00	9.00	9.00	6.00
配当性向 (%)	31.4	—	67.3	60.6	263.3	—
PER (倍)	16.7	(9.3)	51.2	27.9	102.9	(9.4)
PBR (倍)	1.4	1.0	1.3	1.3	1.2	1.0
従業員数 (人)	25,588	26,902	27,828	29,382	29,839	30,396
研究開発人員 (人)	3,392	3,511	3,764	3,933	3,989	3,951
連結子会社数 (社)	116	126	143	146	145	162
為替 (円/\$)	114.44	100.71	92.89	85.74	79.08	82.91
ナフサ価格 (円/KL)	61,500	58,900	41,200	47,500	54,900	57,500
海外売上高の地域別内訳 (十億円)						
アジア	591.7	550.5	539.5	744.3	716.3	736.4
北米	46.1	46.1	75.0	165.4	159.9	176.3
欧州	67.6	80.4	71.8	90.5	82.9	78.8
中東・アフリカ	44.1	37.3	21.8	33.2	25.7	24.2
中南米	17.1	18.2	12.3	13.6	14.4	18.8
オセアニア他	22.2	17.3	8.5	9.7	9.7	9.4
合計	788.8	749.8	728.9	1,056.7	1,009.0	1,043.8
海外売上高比率 (%)	41.6	41.9	45.0	53.3	51.8	53.5

(百万円)

	'14/3	'15/3	'16/3	'17/3
¥2,243,794	¥2,376,697	¥2,101,764	¥1,954,283	
100,842	127,346	164,446	134,336	
111,109	157,414	171,217	166,632	
36,977	52,192	81,451	85,482	
2,788,507	2,880,396	2,662,150	2,862,052	
643,297	791,319	766,874	820,318	
934,506	1,118,216	1,090,776	1,162,526	
194,362	260,854	261,172	187,446	
(135,177)	(56,628)	(53,678)	(199,742)	
59,185	204,226	207,494	(12,296)	
(59,084)	(151,465)	(177,956)	(8,122)	
143.4	84.2	103.8	130.1	
115.7	119.2	116.6	110.3	
141.3	147.9	155.8	157.6	
4.5	5.4	7.8	6.9	
1.6	2.2	3.9	4.4	
6.3	6.2	7.4	8.1	
1,074.6	980.2	831.5	875.3	
1.1	0.9	0.8	0.8	
23.1	27.5	28.8	28.7	
5.5	3.8	3.2	4.7	
15.0	19.0	22.6	17.5	
(4.9)	0.7	(2.7)	(1.6)	
6.5	7.3	10.5	10.8	
1.4	1.8	2.9	3.1	
22.62	31.93	49.84	52.31	
393.58	484.17	469.25	501.98	
9.00	9.00	14.00	14.00	
39.8	28.2	28.1	26.8	
16.8	19.4	10.2	11.9	
1.0	1.3	1.1	1.2	
30,745	31,039	31,094	32,536	
3,897	3,855	3,831	4,010	
164	167	160	170	
100.17	109.76	120.15	108.34	
67,300	63,500	42,800	34,700	
883.0	964.0	819.8	742.3	
233.0	257.3	306.2	308.4	
106.7	96.6	82.3	68.5	
29.7	61.9	30.3	22.4	
29.3	36.3	37.9	34.4	
11.2	12.2	12.7	10.7	
1,292.9	1,428.4	1,289.2	1,186.7	
57.6	60.1	61.3	60.7	

国際会計基準 (IFRS)

(百万円)

	'17/3	(監査中) '18/3
売上収益	¥1,939,069	¥2,190,509
コア営業利益	184,547	262,694
営業利益	126,467	250,923
親会社の所有者に帰属する当期利益	76,540	133,768
資産合計	2,878,193	3,068,685
親会社の所有者に帰属する持分合計	812,612	927,141
資本合計	1,115,903	1,252,214
営業活動によるキャッシュ・フロー	185,776	293,250
投資活動によるキャッシュ・フロー	(205,697)	(154,520)
フリー・キャッシュ・フロー	(19,921)	138,730
財務活動によるキャッシュ・フロー	(523)	(94,264)
設備投資額(十億円)	136.3	158.8
減価償却費(十億円)	110.3	107.1
研究開発費(十億円)	158.0	165.3
売上収益コア営業利益率(%)	9.5	12.0
売上収益当期利益率(%)	3.9	6.1
売上収益研究開発費比率(%)	8.1	7.5
有利子負債(十億円)	884.1	842.2
D/Eレシオ(倍)	0.8	0.7
親会社所有者帰属持分比率(%)	28.2	30.2
キャッシュ・フロー対有利子負債比率	4.8	2.9
インタレスト・カバレッジ・レシオ(倍)	16.4	27.8
金融収支(十億円)	(2.2)	(0.5)
ROE(%)	9.8	15.4
ROA(%)	2.8	4.5
基本的1株当たり当期利益(円)	46.81	81.81
1株当たり親会社所有者帰属持分(円)	496.96	567.04
1株当たり配当金(円)	14.00	22.00
配当性向(%)	29.9	26.9
PER(倍)	13.3	7.6
PBR(倍)	1.3	1.1
従業員数(人)	32,536	31,837
研究開発人員(人)	4,010	4,034
連結子会社数(社)	170	178
為替(円/\$)	108.34	110.85
ナフサ価格(円/KL)	34,700	41,900
海外売上収益の地域別内訳(十億円)		
アジア	741.1	842.6
北米	305.8	366.9
欧州	69.1	85.9
中東・アフリカ	22.4	37.4
中南米	34.4	39.5
オセアニア他	10.7	12.4
合計	1,183.4	1,384.7
海外売上収益比率(%)	61.0	63.2

## 財務ハイライト | Financial Summary

### J-GAAP

	'08/3	'09/3	'10/3	'11/3	'12/3	'13/3
Net sales	¥1,896,539	¥1,788,223	¥1,620,915	¥1,982,435	¥1,947,884	¥1,952,492
Operating income	102,397	2,114	51,455	87,957	60,688	45,016
Ordinary income (loss)	92,790	(32,624)	34,957	84,091	50,714	50,252
Net income (loss) attributable to owners of the parent	63,083	(59,164)	14,723	24,434	5,587	(51,076)
Total assets	2,358,929	2,022,553	2,383,906	2,367,314	2,336,953	2,472,091
Shareholders' equity	768,110	544,366	575,368	522,473	486,235	496,500
Net assets	1,006,046	775,628	821,436	758,886	720,901	747,482
Cash flows from operating activities	156,578	78,428	132,872	176,228	124,491	171,595
Cash flows from investing activities	(182,679)	(206,237)	(269,402)	(155,987)	(123,975)	(165,772)
Free cash flow	(26,101)	(127,809)	(136,530)	20,241	516	5,823
Cash flows from financing activities	7,090	112,539	168,709	17,985	2,054	(36,009)
Capital expenditure (billions of yen)	142.5	134.1	103.2	98.7	155.1	116.1
Depreciation and amortization expenses (billions of yen)	125.0	140.7	116.1	147.0	114.9	115.5
Research and development expenses (billions of yen)	105.4	131.1	117.3	138.1	122.3	125.0
Operating margin (%)	5.4	0.1	3.2	4.4	3.1	2.3
Net income ratio to net sales (%)	3.3	(3.3)	0.9	1.2	0.3	(2.6)
Research and development expenses ratio to net sales (%)	5.6	7.3	7.2	7.0	6.3	6.4
Interest-bearing liabilities (billions of yen)	673.9	795.4	997.9	1,040.3	1,053.0	1,060.6
D/E ratio (times)	0.7	1.0	1.2	1.4	1.5	1.4
Shareholders' equity ratio (%)	32.6	26.9	24.1	22.1	20.8	20.1
Ratio of interest-bearing debt to cash flow	4.3	10.1	7.5	5.9	8.5	6.2
Interest coverage ratio (times)	13.2	6.5	11.0	13.7	10.2	13.2
Net interest expenses (billions of yen)	(2.8)	(2.7)	(5.0)	(6.3)	(4.7)	(5.4)
Return on equity (%)	8.1	(9.0)	2.6	4.5	1.1	(10.4)
Return on assets (%)	2.7	(2.7)	0.7	1.0	0.2	(2.1)
Net income (loss) per share (yen)	38.20	(35.84)	8.92	14.86	3.42	(31.25)
Net assets per share (yen)	465.21	329.74	348.52	319.61	297.45	303.74
Cash dividends per share (yen)	12.00	9.00	6.00	9.00	9.00	6.00
Payout ratio (%)	31.4	—	67.3	60.6	263.3	—
Price earnings ratio (times)	16.7	(9.3)	51.2	27.9	102.9	(9.4)
Price book-value ratio (times)	1.4	1.0	1.3	1.3	1.2	1.0
Number of employees	25,588	26,902	27,828	29,382	29,839	30,396
Number of research and development employees	3,392	3,511	3,764	3,933	3,989	3,951
Number of consolidated subsidiaries	116	126	143	146	145	162
Exchange rate (yen/\$)	114.44	100.71	92.89	85.74	79.08	82.91
Naphtha price (yen/KL)	61,500	58,900	41,200	47,500	54,900	57,500
Overseas sales by region (billions of yen)						
Asia	591.7	550.5	539.5	744.3	716.3	736.4
North America	46.1	46.1	75.0	165.4	159.9	176.3
Europe	67.6	80.4	71.8	90.5	82.9	78.8
Middle East and Africa	44.1	37.3	21.8	33.2	25.7	24.2
Central and South America	17.1	18.2	12.3	13.6	14.4	18.8
Oceania and others	22.2	17.3	8.5	9.7	9.7	9.4
Total	788.8	749.8	728.9	1,056.7	1,009.0	1,043.8
Overseas sales ratio (%)	41.6	41.9	45.0	53.3	51.8	53.5

(Millions of yen)

	'14/3	'15/3	'16/3	'17/3
¥2,243,794	¥2,376,697	¥2,101,764	¥1,954,283	
100,842	127,346	164,446	134,336	
111,109	157,414	171,217	166,632	
36,977	52,192	81,451	85,482	
2,788,507	2,880,396	2,662,150	2,862,052	
643,297	791,319	766,874	820,318	
934,506	1,118,216	1,090,776	1,162,526	
194,362	260,854	261,172	187,446	
(135,177)	(56,628)	(53,678)	(199,742)	
59,185	204,226	207,494	(12,296)	
(59,084)	(151,465)	(177,956)	(8,122)	
143.4	84.2	103.8	130.1	
115.7	119.2	116.6	110.3	
141.3	147.9	155.8	157.6	
4.5	5.4	7.8	6.9	
1.6	2.2	3.9	4.4	
6.3	6.2	7.4	8.1	
1,074.6	980.2	831.5	875.3	
1.1	0.9	0.8	0.8	
23.1	27.5	28.8	28.7	
5.5	3.8	3.2	4.7	
15.0	19.0	22.6	17.5	
(4.9)	0.7	(2.7)	(1.6)	
6.5	7.3	10.5	10.8	
1.4	1.8	2.9	3.1	
22.62	31.93	49.84	52.31	
393.58	484.17	469.25	501.98	
9.00	9.00	14.00	14.00	
39.8	28.2	28.1	26.8	
16.8	19.4	10.2	11.9	
1.0	1.3	1.1	1.2	
30,745	31,039	31,094	32,536	
3,897	3,855	3,831	4,010	
164	167	160	170	
100.17	109.76	120.15	108.34	
67,300	63,500	42,800	34,700	
883.0	964.0	819.8	742.3	
233.0	257.3	306.2	308.4	
106.7	96.6	82.3	68.5	
29.7	61.9	30.3	22.4	
29.3	36.3	37.9	34.4	
11.2	12.2	12.7	10.7	
1,292.9	1,428.4	1,289.2	1,186.7	
57.6	60.1	61.3	60.7	

IFRS

(Millions of yen)

	'17/3	(Unaudited) '18/3
Sales revenue	¥1,939,069	¥2,190,509
Core operating income	184,547	262,694
Operating income	126,467	250,923
Net income attributable to owners of the parent	76,540	133,768
Total assets	2,878,193	3,068,685
Equity attributable to owners of the parent	812,612	927,141
Total equity	1,115,903	1,252,214
Cash flows from operating activities	185,776	293,250
Cash flows from investing activities	(205,697)	(154,520)
Free cash flow	(19,921)	138,730
Cash flows from financing activities	(523)	(94,264)
Capital expenditure (billions of yen)	136.3	158.8
Depreciation and amortization expenses (billions of yen)	110.3	107.1
Research and development expenses (billions of yen)	158.0	165.3
Core operating income to sales revenue (%)	9.5	12.0
Net income to sales revenue (%)	3.9	6.1
Research and development expenses to sales revenue (%)	8.1	7.5
Interest-bearing liabilities (billions of yen)	884.1	842.2
D/E ratio (times)	0.8	0.7
Equity attributable to owners of the parent to total assets (%)	28.2	30.2
Ratio of interest-bearing debt to cash flow	4.8	2.9
Interest coverage ratio (times)	16.4	27.8
Net interest expenses (billions of yen)	(2.2)	(0.5)
Return on equity (%)	9.8	15.4
Return on assets (%)	2.8	4.5
Basic earnings per share (yen)	46.81	81.81
Equity attributable to owners of the parent per share (yen)	496.96	567.04
Cash dividends per share (yen)	14.00	22.00
Payout ratio (%)	29.9	26.9
Price earnings ratio (times)	13.3	7.6
Price book-value ratio (times)	1.3	1.1
Number of employees	32,536	31,837
Number of research and development employees	4,010	4,034
Number of consolidated subsidiaries	170	178
Exchange rate (yen/\$)	108.34	110.85
Naphtha price (yen/KL)	34,700	41,900
Overseas sales revenue by region (billions of yen)		
Asia	741.1	842.6
North America	305.8	366.9
Europe	69.1	85.9
Middle East and Africa	22.4	37.4
Central and South America	34.4	39.5
Oceania and others	10.7	12.4
Total	1,183.4	1,384.7
Overseas sales revenue ratio (%)	61.0	63.2

## セグメント情報 | Sector Information

			'07/3	'08/3	'09/3
売上高 Net sales	基礎化学 石油化学 エネルギー・機能材料 精密化学 情報電子化学 健康・農業関連事業 医薬品 その他	Basic Chemicals Petrochemicals & Plastics Energy & Functional Materials Fine Chemicals IT-related Chemicals Health & Crop Sciences Pharmaceuticals Others	¥ 314,004 539,065 — 90,882 266,436 198,310 234,546 146,783	¥ 314,718 603,326 — 92,937 297,515 200,378 237,592 150,073	¥ 240,030 552,974 — 80,763 307,121 222,202 235,590 149,543
IFRS 売上収益 IFRS Sales revenue	合計	Total	1,790,026	1,896,539	1,788,223
営業利益 (損失) Operating income (loss)	基礎化学 石油化学 エネルギー・機能材料 精密化学 情報電子化学 健康・農業関連事業 医薬品 その他 消去	Basic Chemicals Petrochemicals & Plastics Energy & Functional Materials Fine Chemicals IT-related Chemicals Health & Crop Sciences Pharmaceuticals Others Elimination	13,483 23,596 — 13,085 3,457 23,251 56,231 8,012 (1,492)	10,559 4,518 — 11,430 6,290 20,914 46,464 3,688 (1,466)	(15,334) (30,337) — 1,629 (996) 24,429 32,350 (7,891) (1,736)
IFRS コア営業利益 IFRS Core operating income	合計	Total	139,623	102,397	2,114
売上高営業利益率 (%) Operating margin (%)	基礎化学 石油化学 エネルギー・機能材料 精密化学 情報電子化学 健康・農業関連事業 医薬品 その他	Basic Chemicals Petrochemicals & Plastics Energy & Functional Materials Fine Chemicals IT-related Chemicals Health & Crop Sciences Pharmaceuticals Others	4.29 4.38 — 14.40 1.30 11.72 23.97 5.46	3.36 0.75 — 12.30 2.11 10.44 19.56 2.46	(6.39) (5.49) — 2.02 (0.32) 10.99 13.73 (5.28)
IFRS 売上収益コア営業利益率 (%) IFRS Core operating income to sales revenue (%)	合計	Total	7.80	5.40	0.12
設備投資額 (十億円) Capital expenditure (billions of yen)	基礎化学 石油化学 エネルギー・機能材料 精密化学 情報電子化学 健康・農業関連事業 医薬品 その他	Basic Chemicals Petrochemicals & Plastics Energy & Functional Materials Fine Chemicals IT-related Chemicals Health & Crop Sciences Pharmaceuticals Others	24.6 16.9 — 4.6 72.0 10.1 12.5 19.1	27.6 21.2 — 6.9 33.4 8.5 18.3 26.7	14.7 17.6 — 7.7 50.6 11.3 12.7 19.6
設備投資額の内訳 (十億円) Breakdown of capital expenditure (billions of yen)	新設・増強 基礎化学 石油化学 エネルギー・機能材料 精密化学 情報電子化学 健康・農業関連事業 医薬品 その他 小計	New plants and expansions Basic Chemicals Petrochemicals & Plastics Energy & Functional Materials Fine Chemicals IT-related Chemicals Health & Crop Sciences Pharmaceuticals Others Sub-total	18.7 4.3 — 1.9 66.6 4.7 1.9 5.5 103.6	13.1 1.3 — 3.1 27.6 2.1 11.2 3.2 61.6	3.8 2.9 — 3.3 47.9 2.0 2.9 5.6 68.4
	合理化 研究開発 更新・補修 その他 合計	Rationalization of production processes R&D Maintenance and renewal Others Total	6.8 7.1 22.6 19.8 159.8	5.1 6.5 37.8 31.4 142.5	6.0 9.6 23.0 27.2 134.1
減価償却費 (十億円) Depreciation and amortization expenses (billions of yen)	基礎化学 石油化学 エネルギー・機能材料 精密化学 情報電子化学 健康・農業関連事業 医薬品 その他	Basic Chemicals Petrochemicals & Plastics Energy & Functional Materials Fine Chemicals IT-related Chemicals Health & Crop Sciences Pharmaceuticals Others	13.5 19.2 — 6.5 31.5 14.2 16.2 12.8	13.2 18.4 — 6.1 42.2 12.8 15.4 16.9	17.2 20.9 — 6.3 39.8 13.1 14.5 29.0
IFRS 減価償却費	合計	Total	113.9	125.0	140.7
研究開発費 (十億円) Research and development expenses (billions of yen)	基礎化学 石油化学 エネルギー・機能材料 精密化学 情報電子化学 健康・農業関連事業 医薬品 その他	Basic Chemicals Petrochemicals & Plastics Energy & Functional Materials Fine Chemicals IT-related Chemicals Health & Crop Sciences Pharmaceuticals Others	5.7 11.3 — 4.2 12.6 18.7 42.5 2.6	6.1 11.1 — 4.1 13.7 19.4 47.8 3.2	6.4 12.0 — 4.2 21.2 20.7 55.0 11.6
IFRS 研究開発費	合計	Total	97.7	105.4	131.1

\*1 2011年3月期から全社共通研究費の配賦方法等を見直している。また一部の連結子会社を「その他部門」からセグメントを変更している(2010年3月期は組替後を掲載)。

\*2 2012年3月期から「精密化学部門」を廃止・再編し、同セグメントの事業を「基礎化学部門」と「農業化学部門」に移管、また「農業化学部門」を「健康・農業関連事業部門」に改称(2011年3月期は組替後を掲載)。

\*3 2016年3月期から、従来の基礎化学部門および石油化学部門の事業を「石油化学事業」と「エネルギー・機能材料事業」に再編し、両事業部門を「石油化学部門」と「エネルギー・機能材料部門」に改組(2015年3月期は組替後を掲載)。

\*4 2017年3月期から、情報電子化学部門に含まれていた電池部材およびエンジニアリングプラスチックをエネルギー・機能材料部門に移管(2016年3月期は組替後を掲載)。

(百万円 Millions of yen)

(百万円 Millions of yen)

## 日本基準 (J-GAAP)

## 国際会計基準 (IFRS)

日本基準 (J-GAAP)									国際会計基準 (IFRS)	
'10/3 <sup>*1</sup>	'11/3 <sup>*1,2</sup>	'12/3 <sup>*2</sup>	'13/3	'14/3	'15/3 <sup>*3</sup>	'16/3 <sup>*3,4</sup>	'17/3 <sup>*4</sup>		'17/3 <sup>*4</sup>	(監査中 Unaudited) '18/3
¥ 203,294	¥ 302,289	¥ 284,348	¥ 263,522	¥ 286,898	¥ —	¥ —	¥ —	¥ —	¥ —	¥ —
481,529	649,885	672,428	693,859	792,021	932,294	657,093	572,017	557,852	674,116	674,116
—	—	—	—	—	202,844	209,007	205,934	206,414	250,988	250,988
86,713	—	—	—	—	—	—	—	—	—	—
265,226	322,287	293,066	299,968	362,255	405,126	384,532	358,426	358,473	368,709	368,709
211,546	250,806	264,134	262,580	326,967	345,383	359,013	319,271	320,613	339,698	339,698
267,464	410,614	380,518	378,595	418,809	403,562	435,478	444,189	440,974	500,227	500,227
105,143	46,554	53,390	53,968	56,844	87,488	56,641	54,446	54,743	56,771	56,771
1,620,915	1,982,435	1,947,884	1,952,492	2,243,794	2,376,697	2,101,764	1,954,283	1,939,069	2,190,509	2,190,509
1,328	20,627	9,349	(6,391)	(10,867)	—	—	—	—	—	—
(247)	11,130	6,155	(3,232)	4,942	20,809	28,767	26,604	58,884	94,567	94,567
—	—	—	—	—	783	2,809	7,199	6,030	19,189	19,189
3,579	—	—	—	—	—	—	—	—	—	—
6,304	26,138	10,968	11,703	34,898	32,408	19,874	10,325	8,714	12,341	12,341
29,264	23,302	26,495	26,272	38,184	56,117	77,518	46,154	47,440	43,964	43,964
29,889	28,654	20,918	30,857	47,079	29,024	42,686	55,099	69,871	94,786	94,786
6,714	4,128	7,720	7,963	8,373	15,653	7,830	5,705	10,146	11,052	11,052
(25,376)	(26,022)	(20,917)	(22,156)	(21,767)	(27,448)	(15,038)	(16,750)	(16,538)	(13,205)	(13,205)
51,455	87,957	60,688	45,016	100,842	127,346	164,446	134,336	184,547	262,694	262,694
0.65	6.82	3.29	(2.43)	(3.79)	—	—	—	—	—	—
(0.05)	1.71	0.92	(0.47)	0.62	2.23	4.38	4.65	10.56	14.03	14.03
—	—	—	—	—	0.39	1.34	3.50	2.92	7.65	7.65
4.13	—	—	—	—	—	—	—	—	—	—
2.38	8.11	3.74	3.90	9.63	8.00	5.17	2.88	2.43	3.35	3.35
13.83	9.29	10.03	10.01	11.68	16.25	21.59	14.46	14.80	12.94	12.94
11.17	6.98	5.50	8.15	11.24	7.19	9.80	12.40	15.84	18.95	18.95
6.39	8.87	14.46	14.76	14.73	17.89	13.82	10.48	18.53	19.47	19.47
3.17	4.44	3.12	2.31	4.49	5.36	7.82	6.87	9.52	11.99	11.99
12.4	16.6	24.5	33.0	22.7	—	—	—	—	—	—
14.4	13.7	19.6	14.1	17.0	19.7	20.7	27.7	30.6	17.4	17.4
—	—	—	—	—	5.8	20.6	19.1	21.9	22.5	22.5
17.8	—	—	—	—	—	—	—	—	—	—
11.5	27.7	66.9	18.7	51.5	17.5	26.7	33.7	33.5	24.5	24.5
23.2	15.6	19.3	25.1	17.5	16.3	15.5	23.9	24.2	56.3	56.3
7.8	10.5	11.3	14.6	28.7	16.5	13.9	14.9	14.9	21.2	21.2
16.3	14.6	13.5	10.6	6.1	8.3	6.3	10.8	11.1	16.8	16.8
103.2	98.7	155.1	116.1	143.4	84.2	103.8	130.1	136.3	158.8	158.8
—	—	—	—	—	—	—	—	—	—	—
1.2	3.4	6.9	18.1	4.0	—	—	—	—	—	—
1.9	2.3	6.1	6.8	10.2	2.5	1.8	1.5	—	3.2	3.2
—	—	—	—	—	1.1	10.0	11.8	—	14.3	14.3
11.0	—	—	—	—	—	—	—	—	—	—
8.7	23.9	62.2	15.8	48.1	12.9	22.1	29.5	—	21.3	21.3
17.7	7.8	9.2	15.4	8.6	10.6	6.4	12.1	—	38.0	38.0
2.0	0.7	1.7	1.6	1.9	1.6	1.9	2.8	—	3.7	3.7
7.6	5.7	1.0	2.6	0.6	0.9	0.7	1.2	—	6.0	6.0
50.1	43.8	87.1	60.3	73.4	29.6	43.0	58.9	—	86.5	86.5
5.4	4.6	3.9	3.1	4.8	4.5	8.3	3.5	—	2.7	2.7
7.7	6.7	10.6	12.9	13.0	8.3	7.4	7.4	—	12.1	12.1
18.9	23.7	30.3	22.4	27.2	22.7	21.7	25.2	—	31.3	31.3
21.2	19.9	23.2	17.4	25.0	19.1	23.3	35.0	—	26.2	26.2
103.2	98.7	155.1	116.1	143.4	84.2	103.8	130.1	136.3	158.8	158.8
14.2	21.2	14.2	15.5	18.0	—	—	—	—	—	—
19.4	18.4	14.1	13.7	12.8	22.6	22.2	20.1	22.8	23.0	23.0
—	—	—	—	—	12.4	11.8	11.3	12.7	13.9	13.9
7.3	—	—	—	—	—	—	—	—	—	—
23.2	20.3	14.5	17.9	25.0	33.2	35.0	31.8	31.7	29.6	29.6
12.6	22.3	14.6	15.3	17.7	15.4	16.3	17.3	16.2	16.2	16.2
21.2	47.2	42.3	37.1	28.1	20.9	22.2	20.7	15.5	15.1	15.1
18.4	17.7	15.1	15.9	14.1	14.7	9.2	9.1	11.4	9.4	9.4
116.1	147.0	114.9	115.5	115.7	119.2	116.6	110.3	110.3	107.1	107.1
3.5	5.1	5.2	5.8	6.4	—	—	—	—	—	—
8.3	7.6	7.2	7.1	7.6	6.7	6.2	6.0	6.2	6.6	6.6
—	—	—	—	—	8.2	8.0	9.1	9.3	7.5	7.5
4.2	—	—	—	—	—	—	—	—	—	—
11.0	11.6	11.7	12.3	15.0	16.5	16.6	16.0	16.1	17.3	17.3
17.2	21.6	19.7	20.6	22.9	24.9	26.8	27.8	28.2	29.3	29.3
54.9	71.2	59.0	61.1	71.9	72.9	83.7	83.1	82.3	89.3	89.3
18.1	21.1	19.5	18.1	17.6	18.7	14.5	15.5	15.8	15.3	15.3
117.3	138.1	122.3	125.0	141.3	147.9	155.8	157.6	158.0	165.3	165.3

\*1 From FY2010, we have revised our method of allocation of R&D expenses for company-wide projects, etc. Certain consolidated subsidiaries, formerly categorized under the Others sector, have been re-categorized. (FY2009 figures have been recalculated using the revised method for purposes of comparison.)

\*2 As of FY2011, the Fine Chemicals Sector was eliminated and reorganized. The businesses in this sector were transferred to the Basic Chemicals Sector or the Agricultural Chemicals Sector. Following this change the Agricultural Chemicals Sector has changed its name to "Health & Crop Sciences" sector. (The amounts for FY2010 have been reclassified by revised sectors.)

\*3 As of FY2015, the Basic Chemicals Sector was eliminated and businesses in this sector were split and transferred to the Petrochemicals & Plastics Sector and Energy & Functional Materials Sector that was established as a new business sector. In addition, a part of businesses in the Petrochemicals & Plastics Sector was transferred to the Energy & Functional Materials Sector. (The amounts for FY2014 have been reclassified by revised sectors.)

\*4 As of FY2016, battery materials and engineering plastics that had been included in the IT-related Chemicals Sector were transferred to the Energy & Functional Materials Sector. (The amounts for FY2015 have been reclassified by revised sectors.)